Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2012, Article ID 842945, 11 pages
http://dx.doi.org/10.1155/2012/842945
Review Article

Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma

Department of Oncohematology, University of Perugia, Santa Maria Hospital, 05100 Terni, Italy

Received 16 February 2012; Revised 1 May 2012; Accepted 2 May 2012

Academic Editor: Agostino Cortelezzi

Copyright © 2012 Roberta Martiniani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [28 citations]

The following is the list of published articles that have cited the current article.

  • Mohamed Kharfan-Dabaja, Taiga Nishihori, Tea Reljic, Mehdi Hamadani, Rachid Baz, José L. Ochoa-Bayona, Rahul Mhaskar, Benjamin Djulbegovic, and Ambuj KumarCochrane Database of Systematic Reviews, 2013. View at Publisher · View at Google Scholar
  • Hassan A. Al-Jafar, Nadia Abul, Niranjan Kumar, and Adel Al-Awadhi, “Can lenalidomide play a role in the management of scleritis?,” BMJ Case Reports, 2013. View at Publisher · View at Google Scholar
  • X. Chang, Y. Zhu, C. Shi, and A. K. Stewart, “Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma,” Acta Biochimica et Biophysica Sinica, 2013. View at Publisher · View at Google Scholar
  • G. Lu, R. E. Middleton, H. Sun, M. Naniong, C. J. Ott, C. S. Mitsiades, K.-K. Wong, J. E. Bradner, and W. G. Kaelin, “The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins,” Science, 2013. View at Publisher · View at Google Scholar
  • Michaela Semeraro, Erika Vacchelli, Alexander Eggermont, Jerome Galon, Laurence Zitvogel, and Guido Kroemer, “Trial Watch Lenalidomide-based immunochemotherapy,” Oncoimmunology, vol. 2, no. 11, 2013. View at Publisher · View at Google Scholar
  • Federica Rizzo, Giulietta Riboldi, Sabrina Salani, Monica Nizzardo, Chiara Simone, Stefania Corti, and Eva Hedlund, “Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis,” Cellular and Molecular Life Sciences, 2013. View at Publisher · View at Google Scholar
  • John C. Byrd, and Joseph M. Flynnpp. 1958–1978.e7, 2013. View at Publisher · View at Google Scholar
  • Maria Gkotzamanidou, Evangelos Terpos, Efstathios Kastritis, and Meletios Athanasios Dimopoulos, “Hematologic response and stabilization of renal function in a patient with LCDD after Lenalidomide treatment: A novel therapeutic approach?,” Clinical Lymphoma Myeloma and Leukemia, 2014. View at Publisher · View at Google Scholar
  • Maria Caterina Pallotti, Margherita Nannini, Claudio Agostinelli, Simona Leoni, Valerio Di Scioscio, Anna Mandrioli, Cristian Lolli, Maristella Saponara, Stefano Pileri, Luigi Bolondi, Guido Biasco, and Maria Abbondanza Pantaleo, “Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma,” World Journal of Gastroenterology, vol. 20, no. 22, pp. 7049–7054, 2014. View at Publisher · View at Google Scholar
  • Masahisa Jinushi, “Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses,” Cancer and Metastasis Reviews, 2014. View at Publisher · View at Google Scholar
  • Taxiarchis V. Kourelis, Shaji K. Kumar, Geetika Srivastava, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, Suzanne R. Hayman, Steven R. Zeldenrust, Nelson Leung, Robert A. Kyle, Stephen J. Russell, David Dingli, John A. Lust, Yi Lin, Prashant Kapoor, Ronald Go, S. Vincent Rajkumar, and Angela Dispenzieri, “Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy,” American Journal of Hematology, 2014. View at Publisher · View at Google Scholar
  • Yvonne Mary Papamerkouriou, Eustathios Kenanidis, Zakareya Gamie, Kyriakos Papavasiliou, Thomas Kostakos, Michael Potoupnis, Ioannis Sarris, Eleftherios Tsiridis, and John Kyrkos, “Treatment of multiple myeloma bone disease: experimental and clinical data,” Expert Opinion on Biological Therapy, pp. 1–18, 2014. View at Publisher · View at Google Scholar
  • Michaela Semeraro, and Lorenzo Galluzzi, “Novel insights into the mechanism of action of lenalidomide,” OncoImmunology, vol. 3, no. 1, pp. e28386, 2014. View at Publisher · View at Google Scholar
  • Lohith S. Bachegowda, and Stefan K. Barta, “Genetic and molecular targets in lymphoma: implications for prognosis and treatment,” Future Oncology, vol. 10, no. 15, pp. 2509–2528, 2014. View at Publisher · View at Google Scholar
  • Piotr Smolewski, Magdalena Witkowska, and Tadeusz Robak, “Treatment options for mantle cell lymphoma,” Expert Opinion on Pharmacotherapy, vol. 16, no. 16, pp. 2497–2507, 2015. View at Publisher · View at Google Scholar
  • Kyle T. Helzer, Christopher Hooper, Shigeki Miyamoto, and Elaine T. Alarid, “Ubiquitylation of nuclear receptors: new linkages and therapeutic implications,” Journal Of Molecular Endocrinology, vol. 54, no. 3, pp. R151–R167, 2015. View at Publisher · View at Google Scholar
  • Nilanjan Ghosh, Michael R. Grunwald, Omotayo Fasan, and Manisha Bhutani, “Expanding role of lenalidomide in hematologic malignancies,” Cancer Management and Research, vol. 7, pp. 105–119, 2015. View at Publisher · View at Google Scholar
  • Elvira Valera, Michael Mante, Scott Anderson, Edward Rockenstein, and Eliezer Masliah, “Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease,” Journal Of Neuroinflammation, vol. 12, 2015. View at Publisher · View at Google Scholar
  • María J Cejalvo, and Javier de la Rubia, “Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma,” Future Oncology, pp. 1–16, 2015. View at Publisher · View at Google Scholar
  • K.M. Kortüm, Y.X. Zhu, C.X. Shi, P. Jedlowski, and A.K. Stewart, “Cereblon binding molecules in multiple myeloma,” Blood Reviews, 2015. View at Publisher · View at Google Scholar
  • Magdalena Witkowska, and Piotr Smolewski, “Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma,” Immunotherapy, vol. 7, no. 1, pp. 37–46, 2015. View at Publisher · View at Google Scholar
  • Valérie Pourcher, Aude Desnoyer, Lambert Assoumou, Céleste Lebbe, Angélique Curjol, Anne-Geneviève Marcelin, Fanny Cardon, Séverine Gibowski, Dominique Salmon, Jean-Marie Chennebault, Isabelle Poizot-Martin, Gilles Peytavin, François Boué, and Dominique Costagliola, “Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial,” AIDS Research and Human Retroviruses, 2016. View at Publisher · View at Google Scholar
  • Wolfgang Willenbacher, Shanmugapriya Thangavadivel, Richard Greil, Ella Willenbacher, Roman Weger, Claudia Manzl, Karin Jöhrer, and Andrea Brunner, “Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR),” Leukemia & Lymphoma, pp. 1–12, 2016. View at Publisher · View at Google Scholar
  • Mohamed Kharfan-Dabaja, Taiga Nishihori, Tea Reljic, Mehdi Hamadani, Rachid Baz, José L. Ochoa-Bayona, Rahul Mhaskar, Benjamin Djulbegovic, and Ambuj KumarCochrane Database of Systematic Reviews, 2016. View at Publisher · View at Google Scholar
  • Tristan M. Sissung, Cody J. Peer, Neha Korde, Sham Mailankody, Dickran Kazandjian, David J. Venzon, Ola Landgren, and William D. Figg, “Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms,” Cancer Chemotherapy and Pharmacology, 2017. View at Publisher · View at Google Scholar
  • Wataru Munakata, and Kensei Tobinai, “New Agents of Adult T-cell Leukemia/Lymphoma (ATL),” Adult T-cell Leukemia/Lymphoma, pp. 145–155, 2017. View at Publisher · View at Google Scholar
  • Xiao-Yu Zhai, Yuan-Yuan Guan, Ying-Chao Duan, and Wen-Ping Qin, “Advances in the treatment of cancer by PROTACs,” Yaoxue Xuebao, vol. 52, no. 12, pp. 1801–1810, 2017. View at Publisher · View at Google Scholar
  • Elvira Valera, Brian Spencer, Jerel A. Fields, Ivy Trinh, Anthony Adame, Michael Mante, Edward Rockenstein, Paula Desplats, and Eliezer Masliah, “Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy,” Acta Neuropathologica Communications, vol. 5, no. 1, 2017. View at Publisher · View at Google Scholar